Galiximab
Based on 1 publication(s) in Google Scholar
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.23%
- CAS No.: 357613-77-5
- 분자량:145.24 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Galiximab
More
Biological Activity
제품 설명
Isotype
Human IgG1 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD28L/CD80
In Vitro
Galiximab (25-100 μg/mL; 36 h) in combination with Doxorubicin (HY-15142A) significantly enhances apoptosis in Raji cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raji cells treated Doxorubicin (HY-15142A) (0.05-1 µg/mL)
-
Concentration:25, 50 and 100 μg/mL
-
Incubation Time:36 h
-
Result:Enhanced cell apoptosis in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB17 SCID mice aged 6-8 weeks old treated Raji cells or SKW6.4 cells[1]
-
Dosage:Raji model: 0.1, 1, 3, 10, 30 mg/kg; once weekly; 3 times in total
SKW6.4 model: 5, 10, 30 mg/kg; once weekly; 4 times in total -
Administration:Intraperitoneal injection
-
Result:Showed dose-dependent tumor growth inhibition and survival prolongation in both models.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized B7-1/CD80 Protein, Human (HEK293, HY-P70651) can bind Galiximab, The ED50 for this effect is 2.33 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD28L/CD80 (red) with Galiximab (anti-CD28L/CD80) (HY-P99293). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 357613-77-5
-
Appearance Liquid
-
분자량 145.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Galiximab]
-
Synonyms
IDEC 114; Anti-Human CD80 Recombinant Antibody
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
CD80 (B7-1) as a potential therapeutic target in Epstein-Barr virus‑associated B cell diseases. [Abstract]2026 May 26. PMID: 42191836
순도&문서
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Hariharan K, et al. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Int J Oncol. 2013 Aug;43(2):670-6. [Content Brief]
[2]. Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405-10. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)